Table 3.
Comparison of High- Versus Low-Accruing Sites
| Site Characteristic | High-Accruing Sites (n = 14) |
Low-Accruing Sites (n = 13) |
P | ||
|---|---|---|---|---|---|
| Median | Range | Median | Range | ||
| Annual new analytic case | 1,647 | 526-3,585 | 2,400 | 1,277-3,354 | .47 |
| Collaborations | |||||
| NCI CCOP membership | |||||
| Primary only | 43% | 15% | .21 | ||
| Primary or affiliate | 57% | 38% | .45 | ||
| No. of Cooperative Groups of which site is member | 5 | 1-8 | 3 | 0-6 | .15 |
| NCI CTSU participation | 79% | 62% | .42 | ||
| Funding source (distribution)* | |||||
| Cancer center | 0% | 0%-20% | 10% | 0%-50% | .11 |
| Federal | 46% | 0%-82% | 40% | 0%-75% | .51 |
| Hospital | 0% | 0%-99% | 0% | 0%-75% | .82 |
| Industry | 23% | 0%-65% | 31% | 10%-50% | .49 |
| Philanthropy | 0% | 0%-80% | 0% | 0%-5% | .85 |
| Institutional review board turnaround time, days | 32 | 7-71 | 52 | 10-60 | .18 |
| No. of EP trials open (all sources)† | 39 | 6-66 | 13 | 0-53 | .04 |
Abbreviations: CCOP, Community Clinical Oncology Program; CTSU, Cancer Trials Support Unit; EP, early-phase; NCCCP, National Cancer Institute Community Cancer Centers Program; NCI, National Cancer Institute.
*
Data from 20 sites.
†
Over the course of July 2010-June 2011. Number of open EP trials at a site may also reflect EP trials open at a lead site (eg, a lead CCOP site) with which that NCCCP site is affiliated.